21%) at the same MIC (0.98 μg/mL). In vivo mice (BALB/c) skin infection models showed an 8-fold reduction in MRSA burden after treatment with VCM-OLA-SPDA-micelles when compared with bare VCM. The above results suggest that pH-responsive VCM-OLA-SPDA-micelles has the potential to be an effective carrier to enhance therapeutic outcomes against infections characterised by low pH.Objective To measure differences in post-operative opioid usage and pain scores between pre- and post-Enhanced Recovery after Surgery (ERAS®) radical cystectomy (RC) patients in an effort to optimize outcomes. Study design We performed a retrospective cohort study from a single institution from January 1, 2015 to July 31, 2018 among 86 and 108 pre- and post-ERAS® RC patients. The primary endpoints were total mean opioid usage (Morphine Equivalent Daily Dosing or MEDD) and mean pain scores (Visual Analog Scale or VAS) on post-operative days (POD) 1-3. Secondary endpoints were number of opioid pills prescribed at discharge and within 30 days of discharge. Multivariable model selection was carried out with forward selection and backward elimination to identify variables associated with key outcomes. Results Total mean usage of opioids and mean pain scores were significantly lower in post-ERAS® v. pre-ERAS® patients across POD 1-3, respectively (32.90 MEDD v 99.86 MEDD, p= less then 0.001; 3.51 v 4.17, p=0.003). The median number of opioid pills prescribed at discharge was significantly lower in the post-ERAS® group compared to pre-ERAS® (30 pills v 45 pills, p=0.046) as well as the median number opioid pills prescribed within 30 days of discharge (40 pills v 50 pills, p=0.001). Conclusion Our study suggests that a dedicated ERAS® protocol following RC might be superior to traditional, non-ERAS® methods in reducing post-operative opioid use and pain scores.Objective To evaluate the feasibility and safety of performing robotic-assisted laparoscopic partial nephrectomy (RAPN) as outpatient surgery in patients with renal masses. Materials and methods We analyzed RAPN performed by a single surgeon at an academic medical center from July 2018 to June 2019 and identified those individual patients who were discharged on the same day. These cases were then compared to a concurrent inpatient RAPN group. Relationships with outcome analyzed using Fisher's exact test and Student's t test. Results Twenty-three of 84 RAPNs (27.4%) were performed as ambulatory. https://www.selleckchem.com/products/dl-thiorphan.html Mean age was 57.4 years. Average tumor size was 2.24 cm. The mean total operative time was 99.4 minutes. Average estimated blood loss was 51.0 mL. When compared to the cohort of patients who stayed overnight, on multivariate analysis, the tumor size (2.24 ± 0.71 vs 3.65 ± 1.55 cm, P less then 0.001), and operative time (99.5 ± 25.1 vs 131.2 ± 30.8 minutes, P less then 0.001) were less in ambulatory cases. No differences were seen in regards to Charlson comorbidity index, age, gender, body mass index, estimated blood loss, or surgical approach. Within 90 days of postoperative period, the readmission rate for the entire cohort was 0. Conclusion RAPN can be performed safely as ambulatory in select patients with comparable outcome without complication or hospital readmission.Objective To determine how effective routine postoperative blood work is in identifying complications after percutaneous nephrolithotomy (PCNL), the gold standard treatment for large volume stone disease. Although major complication rates are low, hemorrhagic and sepsis-related complications are serious and can occur. Routine post-PCNL complete blood count is routinely performed by most endourologists but may be a low-value practice. Methods A retrospective review was performed of all PCNL procedures at our center over a 3-year period. Patient demographic, stone characteristics and postoperative data were collected and analyzed. Results Three hundred and eighty-five patients (196 female and 189 males) underwent PCNL for the treatment of urolithiasis. Mean age was 55.8 years and mean length of stay in hospital was 1.74 days. Most patients (82.9%) had neither ureteric stent nor percutaneous tube prior to PCNL. Postoperatively, 4 patients (1.0%) required a blood transfusion and 14 patients (3.6%) developed urosepsis. Patients who required either a transfusion or developed urosepsis demonstrated abnormal vital signs (tachycardia, hypotension, or fever) postoperatively. Sixteen patients (4.2%) had normal vital signs but had an extended hospital stay only to monitor abnormal blood work results. None these patients required a transfusion nor developed urosepsis but had a length of stay that was a mean of 1.5 days longer patients with normal postoperative vital signs and blood work. Conclusion Abnormal vital signs alone identified all patients that required transfusion or treatment for urosepsis after PCNL. Routine complete blood count testing postoperatively may not improve detection of infectious or bleeding complications and may prolong hospital admission unnecessarily.Diabetic non healing wounds often result in significant morbidity and mortality. The number of effective targets to detect these wounds are meagre. Slow lymphangiogenesis is one of the complex processes involved in impaired healing of wounds. Long non coding RNAs (lncRNAs) have been importantly recognized for their role in pathological conditions. Multiple studies have proposed that highlight lncRNAs to be crucial molecules in regulating several biological processes and complex diseases. Herein, we investigate the role of lncRNA Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in the progression of diabetic foot ulcer. We report significant reduction in the expression of lncRNA MALAT1 in the infected Diabetic foot ulcers subjects which is positively correlated with the expression of angiogenic factors Nrf2, HIF-1α and VEGF. Further, expression of pro-inflammatory markers TNF-α and IL-6 increased while, the expression of anti-inflammatory marker IL-10 decreased in infected DFU tissues. Involvement of lncRNA MALAT1 in angiogenesis in EA.hy926 cells is demonstrated by silencing the expression of Nrf2, HIF-1α, and VEGF through interference mediated by MALAT1. Similarly, its inflammatory role is demonstrated by silencing the expression of TNF-α, IL-6 and not affecting the expression of IL-10 Further, CRISPR/Cas9 knock out of Nrf2 decreased the expression of lncRNA MALAT1, HIF-1α and VEGF which revealed the association of Nrf2 in regulating MALAT1/HIF-1α loop through positive feedback mechanism. Collectively, our results suggested the role of Nrf2 on MALAT1/HIF-1α loop in the regulation of angiogenesis, which could act as a novel target in the treatment of diabetic wounds.